Comparison of thrice daily biphasic human insulin (30/70) versus basal detemir & bolus aspart in patients with poorly controlled type 2 diabetes mellitus - a pilot study

What Was Tested

The paper reports a study of Insulin Aspart and Insulin Detemir, published as a randomized controlled trial.

Conventionally, biphasic human insulin (30/70, BHI) is used twice daily for the management of patients with diabetes.

However, this regimen is suboptimal to control post-lunch and/or pre-dinner hyperglycaemia in some patients.

Who Took Part

According to the abstract, 50 patients were involved.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

In this open labelled randomized pilot study, 50 patients with uncontrolled T2DM on twice-daily BHI and insulin sensitizers were randomized either to BHI thrice-daily or BB regimen.

How the Study Was Run

In design terms this was a randomized, open-label and pilot study.

Random assignment meant chance, not the researchers, decided who got Insulin Aspart and who got the comparison, which limits bias.

Being open-label, the Insulin Aspart study did not mask who received what.

It is described as a pilot, a small early test of whether a larger Insulin Aspart study would be practical.

What Was Measured

PubMed files the paper under topics including Biphasic Insulins, Blood Glucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hyperglycemia, Hypoglycemic Agents and Insulin Aspart.

What This Means in Plain Language

The paper is a randomized, open-label and pilot study of Insulin Aspart and Insulin Detemir in 50 patients.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2012 (The Indian journal of medical research), a journal based in United States.

More context: the Insulin Aspart compound page and the Insulin Detemir compound page.